|Bid||249.21 x 900|
|Ask||251.81 x 1000|
|Day's range||248.13 - 253.38|
|52-week range||215.90 - 277.29|
|Beta (5Y monthly)||0.58|
|PE ratio (TTM)||46.81|
|Earnings date||02 Feb 2023|
|Forward dividend & yield||3.64 (1.45%)|
|Ex-dividend date||09 Mar 2023|
|1y target est||270.92|
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.